Technical Analysis for GRTS - Gritstone Oncology, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Crossed Above 20 DMA | Bullish | 3.78% | |
Wide Bands | Range Expansion | 3.78% | |
50 DMA Resistance | Bearish | 10.27% | |
Fell Below 20 DMA | Bearish | 10.27% | |
MACD Bearish Signal Line Cross | Bearish | 10.27% | |
Wide Bands | Range Expansion | 10.27% |
Alert | Time |
---|---|
Up 5% | about 9 hours ago |
50 DMA Resistance | about 11 hours ago |
Up 3% | about 12 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Rose Above Previous Day's High | about 12 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/07/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.33 |
52 Week Low | 1.14 |
Average Volume | 2,057,363 |
200-Day Moving Average | 2.01 |
50-Day Moving Average | 2.42 |
20-Day Moving Average | 2.36 |
10-Day Moving Average | 2.38 |
Average True Range | 0.27 |
RSI (14) | 52.61 |
ADX | 17.59 |
+DI | 28.46 |
-DI | 20.07 |
Chandelier Exit (Long, 3 ATRs) | 2.30 |
Chandelier Exit (Short, 3 ATRs) | 2.65 |
Upper Bollinger Bands | 2.87 |
Lower Bollinger Band | 1.85 |
Percent B (%b) | 0.6 |
BandWidth | 43.14 |
MACD Line | 0.02 |
MACD Signal Line | 0.02 |
MACD Histogram | 0.0035 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.82 | ||||
Resistance 3 (R3) | 2.79 | 2.65 | 2.76 | ||
Resistance 2 (R2) | 2.65 | 2.56 | 2.66 | 2.74 | |
Resistance 1 (R1) | 2.56 | 2.50 | 2.60 | 2.59 | 2.72 |
Pivot Point | 2.42 | 2.42 | 2.44 | 2.43 | 2.42 |
Support 1 (S1) | 2.33 | 2.33 | 2.37 | 2.36 | 2.22 |
Support 2 (S2) | 2.19 | 2.27 | 2.20 | 2.20 | |
Support 3 (S3) | 2.10 | 2.19 | 2.18 | ||
Support 4 (S4) | 2.13 |